All In Biotech

Drug Trial Radar · NCT00459537

Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis

A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis

Last checked: Nov 19, 2026Latest source record: May 6, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,029 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,029

Actual

Start

Mar 2007

Primary completion

Jan 2009

Study completion Jan 2009

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Apr 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in patients with mild to moderate toenail onychomycosis, for a total treatment duration of 48 weeks.

Conditions

  • Onychomycosis

Interventions

  • terbinafine hydrogen chlorideDrug

    10 % terbinafine hydrogen chloride (HCL)

  • amorolfine nail lacquerDrug

    5 % amorolfine nail lacquer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 WeeksTime frame: Week 52
  2. Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks.Time frame: Week 52

Locations

10 sites in 10 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Various Cities, Finland

  • Novartis Investigative Site

    Various Cities, France

  • Novartis Investigative Site

    Various Cities, Germany

  • Novartis Investigative Site

    Various Cities, Hungary

  • Novartis Investigative Site

    Various Cities, Iceland

  • Novartis Investigative Site

    Various Cities, Norway

  • Novartis Investigative Site

    Various Cities, Poland

  • Novartis Investigative Site

    Various Cities, Russia

  • Novartis Investigative Site

    Various Cities, Spain

  • Novartis Investigative Site

    Various Cities, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.